The brief

Analyst view

• JUV-161 is in Phase 1 trials for muscle regeneration with an orphan designation for myotonic dystrophy.
• Eli Lilly partnership worth $650M targets frailty and obesity using Juvena's AI-driven discovery platform.
• JUV-112 preclinical candidate promotes fat breakdown without appetite suppression or muscle loss.

Technical approach

As reported

Secretome Platform

Engineered proteins from stem cells

Analyzes proteins secreted by stem cells to identify tissue-repair candidates. Platform discovered 50+ protein candidates.

AI Discovery

JuvNET AI-enabled screening

Machine learning identifies lead candidates from secretome space, narrowing focus to promising tissue-regenerating proteins.

Muscle Mechanism

JUV-161 activates muscle growth

JUV-161 is a fusion protein activating AKT signaling downstream of the insulin receptor, enhancing muscle regeneration and strength.

Metabolic Approach

JUV-112 increases fat breakdown

JUV-112 targets fat breakdown through energy expenditure, unlike GLP-1 agonists that suppress appetite.

Show all 4